Pharmacokinetic disposition of marbofloxacin and danofloxacin in camel (Camelus dromedarius)

Abstract : The pharmacokinetic disposition of marbofloxacin and danofloxacin was studied in camels following a high - dosage administration as a single-dose (one shot) in a two-period crossover studies. Marbofloxacin was administred by intramuscular and intravenous routes @ 8mg/kg body weight. Danofloxacin was administred by sub-cutaneous and intravenous routes @ 6mg/kg body weight. Concentrations of both fluoroquinolones were measured by highperformance liquid chromatography and the data were subjected to kinetics analysis. The plasma disposition of marbofloxacin was best described by a tri-compartmental for intravenous and a bicompartmental open model with first-order for intramuscular dosing. The Peak plasma concentration (Cmax of 39.80 ± 11,29 mg/1 was reached at (Tma×) 1,16 ± 0,460 h after intamuscular administration. The elimination half-life (t1/2 β) and area under curve of concentration (AUQ were 11.97 ± 3.84 h and 320.65 ± 67.93 mg h/1, respectively. Danofloxacin achieved maximum plasma concentration (Cmax) after sub-cutaneous administration of 27.61 ± 5.00 mg/l at (Tmax) 2.54 ± 1.51h. The distribution half-life (t l/2 β) value of 33.77 ± 32.68 h was obtained for danofloxacin. These data were used together with in vivo pharmacokinetic parameters; Cmax and AUC to determine the surrogate markers of antimicrobial activity; C max/MIC and AUC/MIC Taking into account the values obtained for these markers, it was concluded that an intramuscular dose of 8 mg/kg of marbofloxacin and a sub-cutaneous dose of 6mg/kg of danofloxacin could be adequate for the treatment of infectious diseases caused by high susceptible bacteria such Mannheimia haemolytica and Pasteurella multocida in camels.